Prognostic Value of FLT3 -Internal Tandem Duplication Residual Disease in Acute Myeloid Leukemia
Journal of Clinical Oncology · 01.02.2023 · 41 (4) · 756-765
DOI: 10.1200/jco.22.00715 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Oncology, erschienen am 01.02.2023. Verfasst von Tim Grob und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 151-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
PURPOSE The applicability of FLT3-internal tandem duplications ( FLT3-ITD) for assessing measurable residual disease (MRD) in acute myeloid leukemia (AML) in complete remission (CR) has been hampered by patient-specific duplications and potential instability of FLT3-ITD during relapse. Here, we comprehensively investigated the impact of next-generation sequencing (NGS)–based FLT3-ITD MRD detection on treatment outcome in a cohort of patients with newly diagnosed AML in relation to established prognostic factors at diagnosis and other MRD measurements, ie, mutant NPM1 and multiparameter flow cytometry. METHODS In 161 patients with de novo FLT3-ITD AML, NGS was performed at diagnosis and in CR after intensive remission induction treatment. FLT3-ITD MRD status was correlated with the cumulative incidence of relapse and overall survival (OS). RESULTS NGS-based FLT3-ITD MRD was present in 47 of 161 (29%) patients with AML. Presence of FLT3-ITD MRD was associated with increased risk of relapse (4-year cumulative incidence of relapse, 75% FLT3-ITD MRD v 33% no FLT3-ITD MRD; P < .001) and inferior OS (4-year OS, 31% FLT3-ITD MRD v 57% no FLT3-ITD MRD; P < .001). In multivariate analysis, detection of FLT3-ITD MRD in CR confers independent prognostic significance for relapse (hazard ratio, 3.55; P < .001) and OS (hazard ratio 2.51; P = .002). Strikingly, FLT3-ITD MRD exceeds the prognostic value of most generally accepted clinical and molecular prognostic factors, including the FLT3-ITD allelic ratio at diagnosis and MRD assessment by NGS-based mutant NPM1 detection or multiparameter flow cytometry. CONCLUSION NGS-based detection of FLT3-ITD MRD in CR identifies patients with AML with profound risk of relapse and death that outcompetes the significance of most established prognostic factors at diagnosis and during therapy, and furnishes support for FLT3-ITD as a clinically relevant biomarker for dynamic disease risk assessment in AML.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands.
- Department of Hematology, Cancer Center Amsterdam, Amsterdam University Medical Center, Amsterdam, the Netherlands.
- Department of Hematology, Oslo University Hospital, Oslo, Norway.
- Department of Hematology, Isala Hospital, Zwolle, the Netherlands.
- Department of Medical Oncology and Hematology, Comprehensive Cancer Center Zurich, University Hospital Zurich, Zurich, Switzerland.
- Department of Hematology, Maxima Medisch Centrum, Eindhoven, the Netherlands.
ORCID-Profile: Tim Grob, Mathijs A Sanders, Yngvar Fløisand, Markus G Manz, Lidwine W Tick, Violaine Havelange, Bob Löwenberg, Peter J M Valk
Zitieren
APA
Grob, T., Sanders, M. A., Vonk, C. M., Kavelaars, F. G., Rijken, M., Hanekamp, D. W., Gradowska, P. L., Cloos, J., Fløisand, Y., van Marwijk Kooy, M., Manz, M. G., Ossenkoppele, G. J., Tick, L. W., Havelange, V., Löwenberg, B., Jongen-Lavrencic, M., & Valk, P. J. M. (2023). Prognostic Value of FLT3 -Internal Tandem Duplication Residual Disease in Acute Myeloid Leukemia. Journal of Clinical Oncology, 41(4), 756-765. https://doi.org/10.1200/jco.22.00715
Vancouver
Grob T, Sanders MA, Vonk CM, Kavelaars FG, Rijken M, Hanekamp DW, et al. Prognostic Value of FLT3 -Internal Tandem Duplication Residual Disease in Acute Myeloid Leukemia. Journal of Clinical Oncology. 2023;41(4):756-765. doi:10.1200/jco.22.00715
BibTeX
@article{Grob2023,
author = {Grob, Tim and Sanders, Mathijs A and Vonk, Christian M and Kavelaars, Franҫois G and Rijken, Melissa and Hanekamp, Diana W and Gradowska, Patrycja L and Cloos, Jacqueline and Fløisand, Yngvar and van Marwijk Kooy, Marinus and Manz, Markus G and Ossenkoppele, Gert J and Tick, Lidwine W and Havelange, Violaine and Löwenberg, Bob and Jongen-Lavrencic, Mojca and Valk, Peter J M},
title = {Prognostic Value of FLT3 -Internal Tandem Duplication Residual Disease in Acute Myeloid Leukemia},
journal = {Journal of Clinical Oncology},
year = {2023},
volume = {41},
number = {4},
pages = {756--765},
doi = {10.1200/jco.22.00715}
}
EUVIMED